Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhaled Corticosteroid Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 5, 2026, 10:25 AM EDT
Terminated Phase 2 Interventional Results available

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

NCT00656916
View directory record Official record
Conditions
Bronchiolitis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 5, 2026, 10:25 AM EDT
Recruiting No phase listed Observational

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159
View directory record Official record
Conditions
Asthma
Interventions
Procedure: Investigational Procedures
Other
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
56
States / cities
Chandler, Arizona • Mesa, Arizona • Sun City, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

NCT00565266
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, salmeterol xinafoate, beclomethasone dipropionate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

NCT00116402
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone and salmeterol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Sep 5, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

NCT00005777
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
Procedure · Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
5 Minutes to 10 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

NCT04053634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
84
States / cities
Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

NCT05505734
View directory record Official record
Conditions
Asthma
Interventions
BDA MDI, AS MDI
Drug
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 5, 2026, 10:25 AM EDT
Not yet recruiting Not applicable Interventional

Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults

NCT07507435
View directory record Official record
Conditions
HIV, Inhaled Corticosteroid, Proton Pump Inhibitor, Smoking Cessation, Pneumonia
Interventions
E-consult
Other
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boise, Idaho • Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

NCT00096616
View directory record Official record
Conditions
Asthma
Interventions
Combivent® CFC MDI, Albuterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Lakewood, California • Palmdale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma

NCT00414817
View directory record Official record
Conditions
Asthma
Interventions
Automated Phone-Based Refill Reminders
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
14,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma

NCT00294398
View directory record Official record
Conditions
Asthma
Interventions
ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 5, 2026, 10:25 AM EDT
Active, not recruiting Phase 4 Interventional

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689
View directory record Official record
Conditions
Asthma
Interventions
Albuterol and budesonide inhalation aerosol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge

NCT03369847
View directory record Official record
Conditions
Asthma, Pediatric ALL
Interventions
budesonide, beclomethasone
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
Up to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 5, 2026, 10:25 AM EDT
Terminated Phase 4 Interventional

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

NCT00486343
View directory record Official record
Conditions
Asthma
Interventions
Zileuton CR, Placebo
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma

NCT05036733
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment

NCT01537133
View directory record Official record
Conditions
Asthma, Atopy
Interventions
fluticasone, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

NCT01443845
View directory record Official record
Conditions
COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
217
States / cities
Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 5, 2026, 10:25 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

NCT04138758
View directory record Official record
Conditions
COPD
Interventions
Tiotropium bromide + Olodaterol, LABA/ICS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
42,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 5, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Long-acting Beta Agonist Step Down Study

NCT01437995
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone/Salmeterol Diskus, Fluticasone Diskus
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 5, 2026, 10:25 AM EDT
Active, not recruiting Phase 2 Interventional

Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD

NCT05607719
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Bevespi, Bretzri
Drug
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 5, 2026, 10:25 AM EDT